Pancreatic Cancer Research

ResearcherLyon 1 UniversitéActive in the last 2 years

Jean–Marc Phelip

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4232-6039; OpenAlex author ID A5032791410, A5054195758, A5067260629. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
40
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 4 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 10

  1. Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of three French multicenter prospective ran… Co-author DOI 10.1016/j.canlet.2026.218745↗
  2. Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study. Co-author DOI 10.1093/oncolo/oyaf125↗
  3. Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials. Co-author DOI 10.1038/s41416-021-01624-2↗
  4. Early venous thromboembolism is a strong prognostic factor in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-021-03590-x↗
  5. A Low Total Psoas Muscle Area Index Is a Strong Prognostic Factor in Metastatic Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000001796↗
  6. Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. Co-author DOI 10.1200/jco.20.03329↗
  7. Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study. Last author DOI 10.3390/cancers13112797↗
  8. Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. Co-author DOI 10.1177/1756284819878660↗
  9. Impact of diabetes mellitus on clinical presentation and prognosis of pancreatic cancer. First author DOI 10.1016/j.ando.2010.10.001↗
  10. Comparison of adiponectin concentration between pancreatic cancer and colorectal cancer. Co-author DOI 10.3978/j.issn.2078-6891.2011.031↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nicolas Williet · 6 shared papers, 2019–2025 · strength 0.74
  2. Julien Taı̈eb · 5 shared papers, 2019–2026 · strength 0.72
  3. Laëtitia Dahan · 4 shared papers, 2021–2026 · strength 0.63
  4. Jean‐Baptiste Bachet · 4 shared papers, 2021–2026 · strength 0.63
  5. Isabelle Trouilloud · 3 shared papers, 2019–2026 · strength 0.48
  6. Raëf Abdallah · 2 shared papers, 2025–2026 · strength 0.40
  7. Pierre Laurent‐Puig · 2 shared papers, 2022–2026 · strength 0.37
  8. David Malka · 2 shared papers, 2021–2026 · strength 0.34
  9. Olivier Bouché · 2 shared papers, 2021–2026 · strength 0.34
  10. Xavier Roblin · 3 shared papers, 2011–2021 · strength 0.31
  11. Rémy Nicolle · 1 shared paper, 2026 · strength 0.24
  12. Shulin Zhao · 1 shared paper, 2026 · strength 0.24
  13. Jerome F. Cros · 1 shared paper, 2026 · strength 0.24
  14. Louis de Mestier · 1 shared paper, 2026 · strength 0.24
  15. Baiyong Shen · 1 shared paper, 2026 · strength 0.24
  16. Anne‐Laure Pointet · 2 shared papers, 2019–2025 · strength 0.24
  17. Dominique Béchade · 2 shared papers, 2019–2025 · strength 0.24
  18. Simon Pernot · 2 shared papers, 2019–2025 · strength 0.24
  19. David Tougeron · 2 shared papers, 2019–2025 · strength 0.24
  20. Yves Rinaldi · 2 shared papers, 2021–2022 · strength 0.23
  21. Alix Portal · 1 shared paper, 2025 · strength 0.16
  22. Franck Bonnetain · 1 shared paper, 2025 · strength 0.16
  23. Camille Evrard · 1 shared paper, 2025 · strength 0.16
  24. Émilie Soularue · 1 shared paper, 2025 · strength 0.16
  25. Lysiane Marthey · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.